Burkina Faso vs Senegal: Access to anti-retroviral drugs, female
Burkina Faso
98.0%
in 2024
Senegal
98.0%
in 2024
Burkina Faso rank
1st
Senegal rank
1st
Access to anti-retroviral drugs, female over time
- Burkina Faso
- Senegal
How they compare
Burkina Faso currently reports 98.0% against 98.0% in Senegal, a difference of 0.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Senegal ahead.
Burkina Faso ranks 1st and Senegal ranks 1st of 141 countries.
Across the 3 decades both report, Burkina Faso averaged higher in 1 and Senegal in 2.
Head to head by decade
| Decade | Burkina Faso | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.1% | 10.6% | 0.5% | Senegal |
| 2010s | 67.6% | 62.8% | 4.8% | Burkina Faso |
| 2020s | 91.8% | 95.0% | 3.2% | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Burkina Faso or Senegal?
- Burkina Faso, at 98.0% against 98.0% in Senegal as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Burkina Faso and Senegal?
- 0.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Senegal?
- 25 years are reported by both, from 2000 to 2024.
- How do Burkina Faso and Senegal rank globally for access to anti-retroviral drugs, female?
- Burkina Faso ranks 1st and Senegal ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.